Pathologically elevated vasoactive intestinal polypeptide (VIP) plasma levels cause secretory diarrhea with excessive loss of water and electrolyte and is characterized by the typical symptoms of hypokalemia and metabolic acidosis. It rarely occurs in patients with non-pancreatic disease. Despite the clinical severity, diagnosis of a VIP-secreting tumor is often delayed. We herein present a 14-month-old boy having prolonged therapy-resistant secretory diarrhea, persistent hypokalemia with tissue diagnosis of ganglioneuroblastoma and raised plasma VIP-levels.
wjoes than 60 cases of pediatric VIP-secreting tumors. 3 Most of them are either adrenal pheochromocytoma or mixed pheochromocytoma-ganglioneuroma tumors. Mason et al, 4 first described the secretory nature of neuroblastoma and vasoactive intestinal peptide (VIP) can be produced by the mature neurogenic tumors. We herein present a 14 months old boy having prolonged therapyresistant secretory diarrhea, persistent hypokalemia with tissue diagnosis of ganglioneuroblastoma and briefly review the literature.
CASe RepoRT
A 14-month-old boy, weighing 9 kg with advanced symptoms of persistent secretory diarrhea, hypokalemia and metabolic acidosis was referred to us with radiological (computed tomography) diagnosis of retroperitoneal mass. He had growth retardation and was normotensive; extensively evaluated by the physicians. He had one previous ultrasound, reported as normal study without any comment on retroperitoneal mass. He had low grade on/off fever, abdominal pain and persistent watery diarrhea (~25 times/day; > 1000 ml/day; osmolar gap < 50 mOsm/kg). Stool was brownish in color and was odorless. Abdomen was distended but soft and mass was felt on deep palpation. He accepted oral feeds but needed intravenous (I/V) fluid support along with oral and I/V potassium. Lab reports showed low hematocrit, plasma potassium and sodium levels (Hemoglobin-8 gm%, TLC-22000 Cm, Sodium-132, Potassium-2.7, S Ferritin-32 microgm/l, S LDH-1270 IU/l). (Figs 2A and B) . Contrast enhanced computed tomography-chest, bone scan and bone marrow examination was normal without any evidence of metastasis. Child was resuscitated and optimize for neo-adjuvant chemotherapy. High-risk chemotherapy for neuroblastoma (Cyclophosphamide/Cisplatinum/Adriamycin/Etoposide) was tried and after two cycles, child showed partial response with decrease in stool frequency (~10-14 stool/day) which was transient. We continued the chemotherapy for four cycles, but child did not show further improvement and needed continuous IV fluid and electrolyte support. In the view of patient's condition with persistent symptoms, we decided for surgery but parent of child denied for high-risk surgery and asked referral.
DiSCUSSioN
Neuroblastoma is a common solid tumor of childhood and arises from the neural crest cells; along the sympathetic nervous system. It is usually associated with increased production of non-epinephrine and/or its metabolites. 4, 5 Non-pancreatic VIP-secreting neurogenic tumors are described in literature but it is rare. Clinical experience is based mainly on case reports. Watery diarrhea, hypokalemia and achlorhydria (WDHA) syndrome is usually associated with VIP-secreting neurogenic tumors involving the retroperitoneum and mediastinum in children. Vasoactive intestinal peptide is produced mainly by ganglioneuromas, ganglioneuroblastomas, neurofibromas, pheochromocytoma or combination of pheochromocytoma-ganglioneuroma in the adrenal area. 4, 5 In literature, VIP production indicates a favorable prognosis. 6 In contrast to individuals with VIP-secreting pancreatic tumors, patients with neurogenic lesions generally have normal serum levels of pancreatic polypeptide, gastrin, insulin, and somatostatin. [4] [5] [6] A VIPoma (also known as Verner Morrison syndrome) is a rare endocrine tumor, and usually (about 90%) arise from non-b islet cell of the pancreas, that produce vasoactive intestinal peptide (VIP). 1 Reported incidence is one per 10 million people per year. 7 Vasoactive intestinal peptide, a 28-aminoacid neuropeptide, is expressed in neurons of the gastrointestinal, respiratory, and urogenital tracts and in the central and peripheral nervous system. It inhibits gastric acid secretion, stimulates hepatic glycogenolysis and hyperglycemia, and dilates peripheral systemic blood vessels. High plasma level causes massive secretory diarrhea, dehydration, flushing and weight loss and characteristic laboratory abnormalities include hypokalemia, achlorhydria, hypercalcemia, hyperglycemia and metabolic acidosis (WDHA-syndrome). [1] [2] [3] [4] [5] [6] [7] VIPomas originate in amine precursor uptake and decarboxylation (APUD) cells of the gastroenteropancreatic endocrine system and in adrenal or extraadrenal neurogenic sites. Both chromaffin cells and ganglion cells are derived from the neural crest and have a number of common histochemical and biosynthetic characteristics. VIPomas in adults are usually neuro-endocrine islet cell tumors of the pancreas while in children and adolescents; VIP is produced mainly by ganglioneuromas, ganglioneuroblastomas, neurofibromas, or other tumors in the adrenal area (the most common location) but only a small fraction of neuroblastomas and ganglioneuroblastomas produce VIP. 9 Vasoactive intestinal peptide production indicates a more favorable prognosis. In contrast to individuals with VIP-secreting pancreatic tumors, patients with neurogenic lesions generally have normal serum levels of pancreatic polypeptide, gastrin, insulin, and somatostatin. 9, 10 VIPomas can be part of MEN 1 syndrome but this relationship has not been observed with extra-pancreatic VIP-secreting tumors of childhood. In children, it is extremely rare for a VIPoma to originate in the pancreas; instead, WDHA syndrome is usually associated with VIP-secreting neurogenic tumors involving the retroperitoneum and mediastinum. 11 Pancreatic non-beta-cell hyperplasia is rare but has been reported in children. Hypokalemia and non-anion gap acidosis are the main diagnostic features of VIPomas. Hypokalemia may necessitate aggressive potassium replacement. [9] [10] [11] [12] VIPomas arise from the pancreas in 90% of cases, but they may also be found in periganglionic tissue or at other sites (e.g. colon, bronchus, adrenal glands, and liver), especially in children. 13 They are almost always solitary but < 5% reported to be multicentric. Children with neuroblastomas have a relatively poor overall survival rate (30-40%); children with VIP-secreting ganglioneuroblastomas have a considerably higher survival rate (> 90%). Approximately 50% of surgical patients with VIPoma are cured after tumor resection. In a large series of 241 adult patients with VIPomas, the 5-year survival rate was 89% among those with pancreatic VIPomas and 68.5% among those with neurogenic VIP-producing tumors. 14 In metastatic disease, the 5-year survival rate was 59.6%. Most reports are single cases and suggest a great homogeny within this sub-group of neuroblastic tumors. The stool volume exceeds 700 ml/day in all patients (even during fasting) and 3000 ml/day in approximately 70%. The stools are tea-colored, odorless, with features of a secretory diarrhea, such as persistence with fasting, high sodium concentration and a low stool osmolal gap in a fresh or refrigerated watery stool specimen. An osmotic gap of > 125 mOsm/kg suggests an osmotic diarrhea while a gap of < 50 mOsm/kg suggests a secretory diarrhea. Abdominal pain is mild or absent. The diagnosis of a VIP-secreting tumor is established by the presence of an otherwise unexplained high-volume secretory diarrhea and a serum VIP concentration in excess of 75 pg/ml (10-60 pg/ml). The modern treatment of neuroblastoma is determined based on risk categories. Patients are classified into low, intermediate, and high-risk categories based on the following characteristics at the time of diagnosis: stage of the disease, patient age, histologic appearance of the tumor, presence or absence of amplification of the N-myc proto-oncogene, quantitative deoxyribonucleic acid content of the tumor (DNA index or ploidy).
Our patient had watery diarrhea from last 3 months before referral and extensively evaluated and treated (including i/v Octreotide) by pediatricians. He underwent various hematological and laboratory tests including endoscopic duodenal and colonic biopsies for definite diagnosis. Radiologist could not see the initial retroperitoneal mass on ultrasound, probably because of excessive bowel gas in dilated bowel loops due to hypokalemia. Finally, CECT-abdomen of patient showed the mass and they referred patient to us. Computed tomography-guided core biopsy from mass and its histopathological examination along with its positivity for chromogranin A on immunohistochemistry clinched the diagnosis as VIP-secreting ganglioneuroblastoma. The recommended treatment is complete surgical extirpation with or without chemotherapy. As tumor was extensive (high-risk category) and located near celiac axis, we tried chemotherapy to reduce the size of mass and decrease/ control the symptom of patient. Ganglioneuroblastoma is known to chemosensitive. Chemotherapy showed partial and transient effect and we decided for surgery (at least debulk the mass to control symptoms) but parents denied for high-risk surgery.
We concluded that in all patients with drug-resistant secretory diarrhea with hypokalemia and metabolic acidosis, VIP-secreting neurogenic tumors including ganglioneuroma/ganglioneuroblastoma/neuroblastoma should be considered. Diagnostic work-up must include CT along with other appropriate investigations.
